Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant H7 hemagglutinin influenza vaccine + Advax-2 adjuvant
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine consisting of a **recombinant H7 hemagglutinin influenza antigen** and the **Advax-2 adjuvant**, which is based on crystalline delta inulin polysaccharide. The recombinant H7 hemagglutinin is engineered to elicit an immune response against H7 subtype influenza viruses (notably H7N9), while Advax-2 is designed to enhance immune responses by promoting both Th1 and Th2 immunity. The recombinant hemagglutinin functions as a target for neutralizing antibodies, and the Advax-2 adjuvant boosts the immune response by enhancing antigen presentation and co-stimulatory signals without significant inflammatory cytokine induction. Animal studies demonstrate robust antibody production and protection from lethal H7N9 challenge, including efficacy in neonates. This formulation is being developed as a pandemic and seasonal influenza vaccine platform, particularly addressing the poor immunogenicity of unadjuvanted recombinant protein vaccines[1][4].
- Other names
- recombinant H7N9 hemagglutinin influenza vaccine plus Advax-2rH7HA + Advax-2
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on recombinant H7 hemagglutinin influenza vaccine + Advax-2 adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant H7 hemagglutinin influenza vaccine + Advax-2 adjuvant.